AstraZeneca expands cancer immunotherapy with Innate deal
The drugmaker is buying a 9.8 percent stake in biotech company Innate Pharma, which is run by former AstraZeneca executive Mondher Mahjoubi
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news
More News: AstraZeneca | Biotechnology | Cancer | Cancer & Oncology | Immunotherapy | Pharmaceuticals